With Novartis AG’s cancer treatment Votrient (pazopanib) set for patent expiry in markets including India later this year, there are signs of competition building up in the wings.
Novartis Seeks To Block Alleged Infringer Of Votrient Patent In India
Just months ahead of the patent expiry for Votrient in India, Novartis hauls alleged infringer MSN Laboratories to court, which has bound the Indian firm by its pre-launch assurance for the anticancer therapy.
